Lilly France S.A.S
France Updated 9 July 2026
Lilly France S.A.S is a finished-dose manufacturer based in France. It appears in 3 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with MINSA (CR), NPRA (MY) and DIGEMAPS (DO). Its GMP standing is certified by NAFDAC (NG), EMA and ANVISA (Brazil), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 29 September 2023 as VAI.
3
registered plants
1 with an FDA FEI number
3
filings
across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 29 September 2023 VAI US FDA
- 15 January 2021 VAI US FDA
- 4 April 2017 VAI US FDA
- 3 May 2016 VAI US FDA
- 16 September 2014 NAI US FDA
- 28 September 2012 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| FEGERSHEIM, France | Not on file |
| France, France | 3002807475 |
| Fegershiem, Nigeria | Not on file |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| MINSA (CR) | 1 | None |
| NPRA (MY) | 1 | None |
| DIGEMAPS (DO) | 1 | None |
| NAFDAC (NG) | None | 1 |
| EMA | None | 1 |
| ANVISA (Brazil) | None | 1 |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Lilly France S.A.S comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 29 September 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates